What is HC Wainwright’s Forecast for AXSM FY2025 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at HC Wainwright upped their FY2025 EPS estimates for Axsome Therapeutics in a research note issued on Tuesday, January 20th. HC Wainwright analyst R. Selvaraju now forecasts that the company will earn ($3.31) per share for the year, up from their previous estimate of ($3.49). HC Wainwright currently has a “Buy” rating and a $260.00 target price on the stock. The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2025 earnings at ($0.34) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at $0.51 EPS and Q3 2026 earnings at $1.46 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The firm had revenue of $170.99 million for the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative net margin of 40.90% and a negative return on equity of 277.31%. Axsome Therapeutics’s quarterly revenue was up 63.2% compared to the same quarter last year.

AXSM has been the topic of a number of other reports. Needham & Company LLC reaffirmed a “buy” rating and set a $225.00 price target on shares of Axsome Therapeutics in a report on Monday, January 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Axsome Therapeutics in a report on Wednesday, January 14th. B. Riley began coverage on Axsome Therapeutics in a research report on Wednesday, October 1st. They issued a “buy” rating and a $179.00 target price for the company. TD Cowen reaffirmed a “buy” rating on shares of Axsome Therapeutics in a report on Wednesday, December 31st. Finally, UBS Group lifted their price target on shares of Axsome Therapeutics from $163.00 to $248.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Nineteen investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $203.17.

Axsome Therapeutics Stock Performance

Shares of AXSM opened at $185.96 on Thursday. The company has a market cap of $9.37 billion, a price-to-earnings ratio of -39.82, a P/E/G ratio of 9.86 and a beta of 0.44. The business’s fifty day simple moving average is $159.39 and its two-hundred day simple moving average is $133.10. Axsome Therapeutics has a 12 month low of $86.99 and a 12 month high of $191.50. The company has a current ratio of 1.57, a quick ratio of 1.50 and a debt-to-equity ratio of 1.66.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, Director Mark E. Saad sold 37,577 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The shares were sold at an average price of $165.18, for a total transaction of $6,206,968.86. Following the completion of the sale, the director directly owned 10,002 shares of the company’s stock, valued at approximately $1,652,130.36. This represents a 78.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the sale, the chief financial officer directly owned 42,588 shares of the company’s stock, valued at approximately $8,003,136.96. This represents a 21.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 440,403 shares of company stock worth $67,191,178 over the last 90 days. 22.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Axsome Therapeutics

A number of hedge funds have recently modified their holdings of the business. Versant Capital Management Inc raised its holdings in Axsome Therapeutics by 20,300.0% in the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after purchasing an additional 203 shares during the period. First Horizon Corp bought a new stake in Axsome Therapeutics during the third quarter valued at about $34,000. Optiver Holding B.V. increased its position in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock worth $35,000 after buying an additional 130 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in Axsome Therapeutics in the third quarter worth about $38,000. Finally, Advisory Services Network LLC bought a new position in shares of Axsome Therapeutics in the third quarter worth about $40,000. Institutional investors own 81.49% of the company’s stock.

Axsome Therapeutics News Summary

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.